Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Q1 FY2026 Earnings Presentation
18 slides from Fermenta Biotech's earnings presentation, Aug 13, 2025
Slide 1: Intimation of Earnings Presentation to BSE
Ref: F.No.:908 August 13, 2025 Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Earnings Presentation for Quarter 1 of Financial Year (‘FY’) 2025-26 [Q1/-FY26] Ref: Scrip Code: 506414 Further to our intimation dated August
Slide 2: Q1/FY26 presentation
Fermenta Biotech Ltd Q1/FY26 presentation 13 August 2025
Slide 3: Disclaimer
Disclaimer By viewing this presentation, the recipient agrees that neither Fermenta Biotech Limited (“FBL”) nor any of its affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on t
Slide 4: Best-in-class nutritional ingredients for the world's leading brands
Fermenta provides best-in-class, scientifically-validated nutritional ingredients for the world’s leading brands in the pharmaceutical, dietary supplements, food and beverage, veterinary, and animal feed industries. Our edge? Decades of expertise in global-scale, complex manufacturing, and research-
Slide 5: Q1/FY26 Highlights: Financials without Real Estate and Operational
Q1/FY26 Highlights Financials (consolidated) without Real Estate Operational Human nutrition volume grew by 83% over Q1FY25 and 8% over Q4FY25. Q1FY26 Animal nutrition volume grew by 45 % over Q1FY25 and down by 17% over Q4FY25. INR 141.5 crore Revenue (up 81% YoY, up 6% QoQ) German subsidiary’s sta
Slide 6: Q1/FY26 Highlights: Financials with Real Estate
Q1/FY26 Highlights Financials (consolidated) with Real Estate Q1FY26 INR 145 crore Revenue* (up 79 % YoY, up 1 % QoQ) INR 37 crore EBITDA* (up 922% YoY, down 9 % QoQ) INR 21.6 crore Profit after tax** (vs INR 5.9 crore loss year ago, down 35% QoQ INR 7.49 EPS after exceptional item** (up INR 9.5 YoY
Slide 7: Revenue Mix (Consolidated)
Revenue Mix (Consolidated) Line of Business Geography Q1FY26 Q1FY25 YoY Q4FY25 QoQ (INR (INR change (INR Change crore) crore) (%) crore) (%) Nutrition Business 114.6 62.1 85% 107.7 6% 21% (2)% 19% Vitamin D3 – Human 84.7 46.0 84% 75.4 12% Nutrition 3% Vitamin D3 – Animal 21.4 6.0 256% 23.4 (9)% 10%
Slide 8: Income Statement—Key Numbers (Consolidated)
Income Statement—Key Numbers (Consolidated) Amount in INR crores Q1FY26 Q1FY25 % Change INCOME Revenue from operations 136 78 Growth in human & animal Other income 9 3 nutrition volumes with Total Income 145 81 79% control on the costs helped EXPENSES achieving turnaround Cost of materials consumed
Slide 9: Lines of Business
Lines of Business Driving innovation across Nutritional Wellness, Health, and Environmental Solutions Nutrition Primary revenue source focused on nutritional ingredients for health and wellness industries Vitamin D3 – Human Vitamin D3 – Animal Others Numerous applications in Specialized pre-formulat
Slide 10: Manufacturing and R&D
Manufacturing and R&D Enzymes and APIs including Vitamin D3 Customized premix plant Multiple global regulatory certifications Kullu Dedicated Vitamin D3 with backward Himachal Pradesh integration for cholesterol Multiple global regulatory Collaboration with toll certifications manufacturer for Vitam
Slide 11: Strategic Partnership Ecosystem
Strategic Partnership Ecosystem The Collaboration Strategic Value Global healthcare company Vitamin D awareness campaigns Extends our reach to healthcare Abbott specializing in diagnostics, Print and audiovisual educational materials professionals and patients medical devices, and nutrition Premier
Slide 12: Certifications
Certifications Comprehensive certifications demonstrate our commitment to meet diverse customer needs and global standards of quality, safety, sustainability, and ethical production. Adherence to stringent guidelines for GMP approval for dietary supplements European pharmaceutical markets Confirms i
Slide 13: Fermenta's Value Proposition
Fermenta’s Value Proposition Society Contribute to global health and preventive care through nutritional ingredients Support life productivity across human and animal populations Address environmental challenges with custom and green chemistry solutions Best-in-class, science-backed Market leadershi
Slide 14: Strategy Map
Strategy Map Our Mission Global nutritional wellness while creating value for society, customers, and investors. Financial Financial Performance and Drive consistent, industry-leading financial results Investor Value Optimize asset value to maximize investor returns Ensure sustainable growth through
Slide 15: The Opportunity
The Opportunity Leverage Fermenta’s strengths towards meeting evolving consumer needs and regulatory requirements across diverse markets India Global Innovation Drivers Preventive health awareness Nutritional supplements Nutrigenomics Growing middle class Aging drives vitamin D Natural/organic solut
Slide 16: R&D Focus Areas & Achievements
R&D Focus Areas & Achievements Focus Key Achievements Future Directions Calcifediol commercialization API Product pipelines Commercialized 11 products including Vitamin K1, Cholesterol, Lanolin derivatives VITADEE Green Process improvement Cost optimization for Vitamin K1 process VITADEE SD (Spray D
Slide 17: Strategic Portfolio for Future Growth
Strategic Portfolio for Future Growth Spray-Dried Vitamin D3 VITADEE Green Vitamin K1 Customized Premixes ✓ Patented 100,000 IU/g ✓ Plant-based Vitamin D3 with ✓ Strategic expansion into ✓ Equipped with advanced instrumentation pharmaceutical-grade technology clean-label for vegan supplement essenti
Slide 18: Thank you
Thank you Sumesh Gandhi - CFO sumesh.gandhi@fermentabiotech.com Fermenta Biotech Ltd